ARCALIS, Inc.

Minamisoma, Fukushima, Japan
mRNA LNP/Formulation Plasmid DNA Self-amplifying mRNA (saRNA)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: ARCALIS, Inc.

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Minamisoma, Fukushima, Japan
Modalities
mRNA, LNP/Formulation, Plasmid DNA, Self-amplifying mRNA (saRNA)
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About ARCALIS, Inc.

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesmRNA, LNP/Formulation, Plasmid DNA, Self-amplifying mRNA (saRNA)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (4 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (4 modalities)

Frequently Asked Questions About ARCALIS, Inc.

What is ARCALIS, Inc.'s CDMO Signal Score?
ARCALIS, Inc. has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating ARCALIS, Inc. for a manufacturing program?
Use the free AI matchmaker to compare ARCALIS, Inc. against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs → LNP/Formulation CDMOs → Plasmid DNA CDMOs → Self-amplifying mRNA (saRNA) CDMOs →

Similar CDMOs

BioCina
Adelaide, Australia
Biologics (Microbial), Plasmid DNA, mRNA, LNP, Sterile Fill-Finish, Recombinant Proteins, Vaccines, Biosimilars, High Potency/Oncology Injectables, Blow-Fill-Seal
CoJourney Inc.
Ambler, PA (US operations; primary manufacturing in Hangzhou, Zhejiang, China)
Plasmid DNA, AAV, Adenoviral, Lentiviral, Retroviral, mRNA, sgRNA, Exosome
53Biologics
Boecillo, Valladolid, Spain
Biologics, Recombinant Proteins, Plasmid DNA, mRNA, Enzymes, Vaccines, Antibody Fragments
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 91.5
Biologics, mRNA
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA